论文部分内容阅读
目的：探讨Ｐ５３基因突变表达产物与卵巢肿瘤临床生物学行为之间的关系．方法：采用单克隆抗体免疫组化染色方法对５０例卵巢恶性肿瘤，１０例良性肿瘤的石蜡切片标本进行Ｐ５３基因突变蛋白表达检测．结果：卵巢恶性肿瘤Ｐ５３阳性表达率２４％（１２／５０），卵巢良性肿瘤均为阴性卵巢上皮癌阳性结果为２９％（８／２８），生殖细胞瘤１０％（１／１０），间质瘤２５％（２／８），转移瘤２５％（１／４）；不同临床分期阳性表达：Ⅰ期４例，Ⅱ期３例，Ⅲ期２例，Ⅳ期３例；Ｐ５３免疫组化染色阳性家系有癌症史３例（３／１２），阴性者１例（１／３８）．结论：结果表明①各种组织类型的卵巢恶性肿瘤均可出现Ｐ５３阳性表达，似与组织分型无关（Ｐ＞０．５）；②Ｐ５３阳性表达与临床分期无关（Ｐ＞０．２５）；③提示Ｐ５３阳性表达可能与遗传因素有关（Ｐ＝０．０３８）；④Ｐ５３阳性表达与卵巢恶性肿瘤的淋巴结转移未发现明显的相关性．
Objective: To investigate the relationship between the expression of P53 gene and clinical biological behavior of ovarian tumors. Methods: Immunohistochemical staining with monoclonal antibody was used to detect the mutation of P53 gene in 50 cases of ovarian cancer and 10 cases of benign tumor. Results: The positive rate of P53 in ovarian cancer was 24% (12/50), the positive result was 29% (8/28) in benign ovarian tumors, 10% (1/10) in germ cell tumors, 25% (2/8) of tumors and 25% (1/4) of metastases. The positive expression in different clinical stages was: stage Ⅰ in 4 cases, stage Ⅱ in 3 cases, stage Ⅲ in 2 cases and stage Ⅳ in 3 cases. P53 immunohistochemical staining Positive family history of cancer in 3 cases (3/12), negative in 1 case (1/38). Conclusion: The results showed that ① P53 positive expression was found in ovarian malignant tumors of all kinds of tissues, which was not related to tissue typing (P> 0.5); ② The positive expression of p53 was not associated with clinical stage (P> 0.25); ③ Suggesting that P53 positive expression may be related to genetic factors (P = 0.038); ④P53 positive expression and ovarian cancer lymph node metastasis was not significantly correlated.